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Abstract: NK cells play an important role in tumor immunosurveillance. Their reactivity is
governed by various activating and inhibitory surface receptors, which include several members
of the TNF/TNF receptor family. For more than 50 years, it has been recognized that tumor
immunosurveillance and in particular NK cell antitumor reactivity is largely influenced by platelets,
but the underlying mechanisms remain to be fully elucidated. Here we report that upon activation,
which reportedly occurs following interaction with cancer cells, platelets upregulate the TNF family
member RANKL. Comparative analysis of the expression of RANK among different NK cell subsets
and RANKL on platelets in cancer patients and healthy volunteers revealed a distinct malignant
phenotype, and platelet-derived RANKL was found to inhibit the activity of normal NK cells against
cancer cells. Notably, NK cell antitumor reactivity could be partially restored by application of
denosumab, a RANKL-neutralizing antibody approved for treatment of benign and malignant
osteolysis. Together, our data not only unravel a novel mechanism of tumor immune evasion
mediated by platelets, but they also provide a functional explanation for the clinical observation that
denosumab, beyond protecting from bone loss, may prolong disease-free survival in patients with
solid tumors.
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1. Introduction
The key role of platelets in tumor progression and metastasis has been recognized for more than
50 years [1]. Platelets interact with blood-borne tumor cells forming platelet-tumor cell aggregates,
which enhance metastasis via multiple mechanisms. Beyond releasing growth factors/chemokines,
facilitating endothelial adhesion and inducing epithelial-to-mesenchymal transition of tumor cells,
platelets also contribute to immune evasion, another hallmark of cancer [2–4]. Nieswandt and
colleagues observed an inhibition of metastasis formation in thrombopenic mice, while additional
depletion of natural killer (NK) cells reverted this effect, suggesting that platelets guard tumor cells
against elimination by NK cells [5].
NK cell effector function, which is regulated by integration of multiple inhibitory and activating
signals mediated by various immunoregulatory molecules, plays a key role in controlling metastatic
dissemination [6,7]. Among others, several TNF/TNF receptor (TNFR) family members influence the
same [8–11]. In recent studies, we contributed to a better understanding of the mechanisms by which
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platelets facilitate evasion of cancer cells from NK cell immunosurveillance. This comprised analyses
showing that platelet-derived TGF-β downregulates the activating receptor NKG2D on NK cells [12]
and that NKG2D ligands are shed from the tumor cell surface following tumor-platelet interaction [13],
thereby facilitating evasion from the NK cell “induced self” recognition mode [14]. We also reported
that platelets transfer non-malignant MHC class I to tumor cells, which inhibits antitumor immunity
of NK cells expressing respective inhibitory KIR receptors, thereby also impairing “missing self”
recognition of tumor cells [15]. Moreover, we provided first evidence for the involvement of members
of the TNF family in platelet-mediated evasion of tumor cells from NK cell reactivity: we showed that
platelets transfer glucocorticoid-induced TNFR-related ligand (GITRL) to tumor cells, which results in
diminished antitumor immunity due to triggering the GITR receptor that is expressed on and inhibits
reactivity of NK cells [16].
Recently, other investigators reported on the expression of receptor activator of NF-κB ligand
(RANKL) on TRAP6-activated platelets and its role in modulating dendritic cell function [17].
This triggered our interest since its cognate receptor RANK is expressed on NK cells and inhibits their
antitumor reactivity in patients with hematologic malignancies [18,19]. Here we comparatively studied
the expression of various TNF/TNFR family members on platelets and lymphocytes of cancer patients
and healthy controls. We provide evidence that NK cells from patients with solid tumors display
significantly enhanced RANK surface levels and that platelet-derived RANKL impairs NK effector
functions against solid tumors, pointing to a role of platelet-derived RANKL in immune evasion of
solid tumors from NK cell immunosurveillance.
2. Results
2.1. Expression of TNFR Family Molecules on PBMC Subpopulations
Members of the TNF/TNFR family are expressed on different lymphocyte subsets and influence
activation, proliferation, and cell death of the respective cell types [20]. We comparatively analyzed the
expression of several TNFR family molecules that reportedly influence antitumor immunity and for
which antibodies with validated specificity were available, on lymphocyte populations among PBMC
of patients with breast cancer (BC), colorectal carcinoma (CC) and healthy donors (HD). The clinical
characteristics of the patients are given in Table 1. For CD40, no relevant expression was detected on B,
T, and NK cells (Figure 1A). GITR and OX40 were expressed at intermediate levels and HVEM was
expressed at high levels on all the analyzed cell populations. No profound differences were observed
between patients and HD, even if biometrical analysis revealed a small statistically significant difference
for HVEM in T cells of CC and OX40 in T cells of BC patients compared to HD (BC, p = 0.0125, ordinary
one-way ANOVA with subsequent Dunnett’s multiple comparisons test; CC, p = 0.0206, Kruskal-Wallis
test with subsequent Dunnett’s multiple comparisons test). In sharp contrast, RANK was expressed
at intermediate (B and T cells) to high (NK cells) levels on all lymphocyte subsets from BC and CC
patients, which differed significantly from HD who displayed only minimal RANK levels (B cells, BC
p = 0.0069 and CC p = 0.0008; T cells, BC p = 0.0062 and CC p = 0.0037; NK cells, BC p = 0.0003 and CC
p = 0.0160; all Kruskal-Wallis test with subsequent Dunnett’s multiple comparisons test).
To mimic the autocrine and paracrine signaling physiologically occurring among immune cells,
we next determined how the TNFR expression profile of B, T, and NK cells among PBMC of HD
was influenced upon culture (Figure 1B). Only minor effects on CD40, GITR, and OX40 expression
were observed with all analyzed lymphocyte populations. For HVEM, a profound downmodulation
was observed on B cells, while there was a slight upregulation in NK cells of some donors. Most
pronounced results were again observed with RANK, for which a profound upregulation on NK cells
was observed in this experimental setting.
As a next step, we investigated the specific expression patterns of the TNFR molecules on
lymphocytes of patients and HD which we consider a phenotypic imprint (Figure 1C). Highly variable
expression patterns among the different individuals were observed in both HD and in cancer patients.
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Most pronounced expression levels were observed for HVEM and RANK. While HVEM was detectable
on all lymphocyte populations of patients as well as HD, RANK levels appeared to be specifically
upregulated on NK cells of BC and CC patients. Of note, RANK surface levels were significantly
higher on CD56dim as compared to CD56bright NK cells, which exert at least partially differing roles
and effector functions in antitumor immunity (Figure 1D; BC, p = 0.0054 and CC, p < 0.0001; both
Student’s t test).
Table 1. Patient characteristics.
BC Patients CC Patients
Patient Characteristics Count % Patient Characteristics Count %
total no. of patients 9 100 total no. of patients 11 100
age (years) age (years)
mean 66 mean 63
range 58–81 range 47–79
sex of patients sex of patients
female 9 100 female 4 36.4
male 0 0 male 7 63.6
UICC stage UICC stage
I 3 33.3 I 0 0
II 1 11.1 II 0 0
III 0 0 III 0 0
IV 5 55.6 IV 11 100
receptor status cytogenetic
Her2 5 55.6 Ras mutation 4 36.4
HR 6 66.7 MSI 0 0
Her2 1 9
PIK3C 1 9
SMAD4 1 9
TP53 2 18
BRAF 1 9
no. treatment regimens exposed
to no. treatment regimens exposed to
1 5 55.6 1 2 18.2
2 1 11.1 2 5 45.4
≥3 3 33.3 ≥3 4 36.4
thromboembolic event 1 11.1 thromboembolic event 2 18.2
BC, breast cancer; no., number; UICC, Union Internationale Contre le Cancer; Her2, human epidermal growth factor
receptor 2; HR, hormone receptor; CC, colorectal cancer; MSI, microsatellite instability; PIK3C, phosphatidylinositol
3-kinase; SMAD4, SMAD family member 4; TP53, tumor protein 53; BRAF, v-raf murine sarcoma viral oncogene
homolog B.
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Figure 1. Expression of TNFR family molecules on PBMC subpopulations. (A,C,D) CD40, GITR, 
HVEM, OX40, and RANK surface expression on PBMC subpopulations from BC and CC patients 
and HD were investigated by flow cytometry (n = 6, 6, and 9, respectively). (A) The percentage of 
surface expression is indicated. (B) PBMC from five HD were freshly isolated or cultured without 
treatment for three days and CD40, GITR, HVEM, OX40, and RANK surface expression was 
determined by flow cytometry. Results were comparatively analyzed as follows: “percent surface 
expression of cultured PBMC” − “percent surface expression of freshly isolated PBMC”. The net 
modulation is depicted as heatmap. (C) Heatmap analysis of the surface expression profiles among 
PBMC of individual patients (disease stage as described in Table 1) and HD investigated. (D) The 
percentage of RANK surface expression on CD56bright and CD56dim NK cell subsets is displayed. 
(A,D) Median values of the respective group are depicted. Statistically significantly different results 
(p < 0.05) are indicated by *. 
Figure 1. Expression of T F fa ily olecules on PB subpopulations. (A,C,D) CD40, GITR,
HVEM, OX40, and RANK surface expression on PBMC subpopulations from BC and CC patients and
HD were investigated by flow cytometry (n = 6, 6, and 9, respectively). (A) The percentage of surface
expression is indicated. (B) PBMC from five HD were freshly isolated or cultured without treatment
for three days and CD40, GITR, HVEM, OX40, and RANK surface expression was determined by flow
cytometry. Results ere comparatively analyzed as follows: “percent surface expression of cultured
PBMC” − “percent surface expression of freshly isolated PBMC”. The net modulation is depicted as
heatmap. (C) Heatmap analysis of the surface expression profiles among PBMC of individual patients
(disease stage as described in Table 1) and HD investigated. (D) The percentage of RANK surface
expression on CD56bright and CD56dim NK cell subsets is displayed. (A,D) Median values of the
respective group are depicted. Statistically significantly different results (p < 0.05) are indicated by *.
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2.2. Functional Effects of the RANK/RANKL Axis in NK Cell Reactivity Against Solid Tumors
The analyses described above point to a potential role of RANK in NK cell-mediated
immunosurveillance of solid tumors. We thus assessed RANK expression on NK cells of the cancer
patients and HD as well as the NK cell line NK92 and ex vivo preactivated polyclonal NK (pNK)
cells that are presently evaluated for cancer treatment [21–23]. While NK cells from HD, alike NK92
cells, displayed no or only minimal percentage of RANK-positive cells, BC and CC patients were
found to have more than 70% RANK-positive NK cells (Figure 2A). Substantial expression of RANK
was also observed with pNK cells, which were used in subsequent functional experiments since
access to primary cells from cancer patients is limited. Notably, since RANK levels on pNK cells from
different donors varied substantially, assays were performed with pNK cells displaying expression
levels comparable to those from BC and CC patients.
To elucidate the functional relevance of RANK, NK cells were cultured with breast (MCF-7) or
colorectal (HCT 116) cancer cells in the presence or absence of recombinant human RANKL (rhRANKL)
to facilitate RANK triggering (Figure 2B). Analysis of culture supernatants revealed that the presence
of tumor cells markedly induced IFNγ production by NK cells, which constitutes an important
effector mechanism by which NK cells shape adaptive immune responses and contribute to tumor
immunosurveillance. RANK signaling significantly reduced cytokine release in this experimental
setting when RANK-positive pNK cells were used as effectors (MCF-7, p = 0.0003; HCT 116, p = 0.0047;
both Student’s t test), while no effects were observed with the RANK-negative NK92 cells.
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Next we determined the effect of RANK signaling on cancer cell proliferation in the presence of
NK cells. To this end, MCF-7 breast cancer cells were cultured with or without pNK cells in the presence
or absence of rhRANKL, which revealed significantly more pronounced tumor cell proliferation upon
RANK signaling (Figure 2C; p < 0.0001, Wilcoxon signed-rank test). Of note, treatment of MCF-7 cells
with rhRANKL alone had no relevant effects on the survival/proliferation of the breast cancer cells
(Supplementary Figure S1A). These data indicate that RANK triggering protects cancer cells from NK
cell attack.
2.3. Expression of TNF Family Members on Platelets
As platelets protect tumor cells from NK cell attack and TNFR family members like the
GITR/GITRL molecule system contribute to the same, we next assessed the expression pattern of the
immunomodulatory TNF family members CD40L, GITRL, LIGHT, OX40L, and RANKL on platelets
from BC and CC patients as well as HD. Exemplary results are shown in Figure 3A. Combined
analysis of data obtained with platelets of ten HD revealed expression levels of CD40L, GITRL, OX40L,
and RANKL (Figure 3B). No relevant LIGHT expression was detected on platelets, which indicates
that the LIGHT/HVEM axis may not act as major mediator of platelet-mediated immune privilege
despite the high HVEM expression observed on the lymphocyte populations from BC and CC patients
(see Figure 1).
Analysis of the specific expression patterns of the TNF family molecules on platelets of the
individual patients and HD, considered by us as specific phenotypic imprint, revealed, alike in the
analyses of the lymphocyte populations, a profound inter-individual variability (Figure 3C). When
the expression of the different TNF family molecules on platelets from BC and CC patients and
HD was comparatively analyzed, we surprisingly found that, except for CD40L in CC, median
relative expression of all analyzed molecules was slightly lower on platelets from BC and CC patients
compared to median results obtained with HD (Figure 3D; BC, OX40L, p = 0.0418; Kruskal-Wallis test
with subsequent Dunnett’s multiple comparisons test). This is seemingly in contrast to available data
that many TNF family members are upregulated on platelets following their stimulation including
interaction with tumor cells [16].
To determine whether and how CD40L, GITRL, LIGHT, OX40L, and RANKL expression was
influenced upon stimulation, platelets were either left untreated or were activated with thrombin
(Figure 3E). Combined analysis of platelets from HD revealed no relevant induction of LIGHT and
CD40L upon activation, while GITRL, RANKL and in particular OX40L appeared to be upregulated.
These data point to an involvement of immunomodulatory TNF family members expressed by platelets
in cancer pathophysiology.
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Figure 3. Expression of TNF family molecules on platelets. (A–D) C 40L, GITRL, LIGHT, OX40L, and
RANKL surface expression on resting platelets from BC and CC patients and HD were investigated
by flow cytometry after fixation with 2% paraformaldehyde (n = 9, 11, and 10, respectively).
(A) Representative results obtained from BC and CC patients and HD are shown. (B) The percentage of
surface expression on platelets from HD is indicated. (C) Heatmap analysis of the expression profiles
among the platelets of individual patients (disease stage as described in Table 1) and HD investigated.
(D) Relative surface expression on platelets from BC and CC patients compared to HD is depicted. For
combined analysis, the median percentage of positive platelets obtained from HD was set to 1 for each
individual TNF family molecule analyzed (dotted lines). (E) The percentage of CD40L, GITRL, LIGHT,
OX40L, and RANKL surface expression on resting (R) or activated (exposure to thrombin for 1 min, A)
platelets from HD was analyzed by flow cytometry after fixation with 2% paraformaldehyde (R, n = 10;
A, n = 6). (B,D) Median values of the respective group are depicted. (D,E) Statistically significantly
different results (p < 0.05) are indicated by *.
2.4. Functional Effect of Platelet-Derived RANKL on NK Reactivity
Based on the expression of RANK and RANKL on NK cells and platelets of cancer patients,
respectively, and the observed impairment of NK reactivity upon RANK triggering, we reasoned
that RANK/RANKL interaction may contribute to the escape of cancer cells from NK cell
immunosurveillance. To elucidate the specific contribution of platelet-derived RANKL in this context,
MCF-7 and HCT 116 cancer cells, which lacked relevant endogenous RANKL expression, were
employed in functional analyses with NK cells in the presence or absence of platelets (Figure 4A).
In line with previous data by us and others [2,12,15,16], both MCF-7 and HCT 116 tumor cells were
rapidly coated upon the encounter of platelets. Moreover, substantial RANKL pseudo- expression
was observed on tumor cells when they were platelet-coated (Figure 4B). The presence of tumor cells
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induced production of IFNγ by NK cells, and this was significantly reduced when the malignant
cells previously had encountered platelets (Figure 4C; MCF-7, p = 0.0177; HCT 116, p = 0.0006; both
Student’s t test). Similarly, a protective effect of the platelets was also observed with regard to tumor
cell survival/proliferation (Figure 4D; p < 0.0001; Wilcoxon signed-rank test). Of note, NK cell/platelet
co-culture supernatants and those from rhRANKL-treated NK cells were found not to have relevant
effects on the growth of MCF-7 cells (Supplementary Figure S1B).
To determine the particular relevance of RANKL in platelet-mediated tumor immune privilege,
we next conducted the functional analyses in the presence of the RANKL-neutralizing antibody
denosumab [24,25] (Figure 4E,F). When the effect of blocking platelet-derived RANKL on tumor cell
proliferation/survival was determined, a statistically significant albeit not relevant effect of denosumab
was observed as compared to the application of a respective isotype control (p < 0.0001; Wilcoxon
signed-rank test). This was in clear contrast to the pronounced effect of RANKL-blockade on NK cell
IFNγ production, where denosumab treatment restored NK cell effector function as compared to the
control (MCF-7, p = 0.0195; HCT 116, p = 0.0058; both Student’s t test).
The effect of denosumab was in fact due to disruption of the platelet-derived RANKL/RANK axis,
since no influence on NK cell reactivity was observed with the RANK-negative NK92 cells (Figure 4G).
Of note, RANKL-blockade and not Fc part-mediated effects augmented NK reactivity against solid
tumors as functional analyses in the presence of denosumab were found not to alter cytokine release
when RANK-negative pNK cells were used in the co-culture (Supplementary Figure S2A,B). Altogether,
our data demonstrate that platelet-derived RANKL impairs NK cell antitumor reactivity with a less
pronounced effect on cytotoxicity compared to production of IFNγ as second major effector mechanism
by which NK cells contribute to tumor immunosurveillance.
Cancers 2019, 11, x 8 of 15 
 
0.0006; both Student’s t test). Similarly, a protective effect of the platelets was also observed with 
regard to tumor cell survival/proliferation (Figure 4D; p < 0.0001; Wilcoxon signed-rank test). Of 
note, NK cell/platelet co-culture supernatants and those from rhRANKL-treated NK cells were 
found not to have relevant effects on the growth of MCF-7 cells (Supplementary Figure S1B). 
To determine the particular relevance of RANKL in platelet-mediated tumor immune privilege, 
we next conducted the functional analyses in the presence of the RANKL-neutralizing antibody 
denosumab [24,25] (Figure 4E,F). When the effect of blocking platelet-derived RANKL on tumor cell 
proliferation/survival was determined, a statistically significant albeit not relevant effect of 
denosumab was observed as compared to the application of a respective isotype control (p < 0.0001; 
Wilcoxon signed-rank test). This was in clear contrast to the pronounced effect of RANKL-blockade 
on NK cell IFNγ production, where denosumab treatment restored NK cell effector function as 
compared to the control (MCF-7, p = 0.0195; HCT 116, p = 0.0058; both Student’s t test). 
The effect of denosumab was in fact due to disruption of the platelet-derived R L/RANK 
axis, since no influence on NK cell reactivity as observed with the RANK-negative NK92 cells 
(Figure 4G). Of note, RANKL-blockade and not Fc part-mediated effects augmented NK reactivity 
against solid tumors as functional analyses in the presence of denosumab were found not to alter 
cytokine release when RANK-negative pNK cells were used in the co-culture (Supplementary 
Figure S2A,B). Altogether, our data demonstrate that platelet-derived RANKL impairs NK cell 
antitumor reactivity with a less pronounced effect on cytotoxicity compared to production of IFNγ 
as second major effector mechanis  by which NK cells contribute to tumor immunosurveillance. 
 
Figure 4. Cont. 
  
Figure 4. Cont.
Cancers 2019, 11, 277 9 of 15
Cancers 2019, 11, x 9 of 15 
 
 
Figure 4. Functional role of platelet-derived RANKL in NK cell reactivity against solid tumors. (A) 
RANKL surface expression on the indicated tumor cells was investigated by flow cytometry. (B–G) 
The indicated tumor cells were incubated in the presence or absence of platelets from HD. Coating 
was performed as described in the Materials and Methods section. (B) RANKL and CD41a surface 
expression on the indicated platelet-coated tumor cells was investigated by flow cytometry. (C) pNK 
cells were cultured in the presence or absence of the indicated tumor cells and platelets from HD. 
IFNγ levels in the culture supernatants were determined by ELISA after 24 h. (D) pNK cells were 
co-cultured with MCF-7 cells in the presence or absence of platelets from HD. The effect of NK cell 
reactivity on tumor cell proliferation/survival was assessed by xCELLigence RTCA for 72 h. Results 
are shown as electrical impedance signal (given as normalized cell index). Cell index was normalized 
after addition of NK cells to the tumor cells. (E) pNK cells were cultured in the presence or absence of 
the indicated tumor cells and platelets from HD. Where denoted, denosumab (10 µg/mL) or the 
respective isotype control was applied. IFNγ levels in the culture supernatants were determined by 
ELISA after 24 h. (F) pNK cells were treated as indicated in (E) and analyzed as in (D). (G) NK92 cells 
were treated and analyzed as described in (E). (C–G) Representative data of one experiment from a 
total of at least three with similar results are shown. Statistically significantly different results  
(p < 0.05) are indicated by *. 
3. Discussion 
RANKL and its cognate receptors RANK and osteoprotegerin play a key role in regulating bone 
metabolism [26]. Besides maintaining bone turnover in normal bone physiology, RANK also 
mediates osteolytic lesions in the context of metastatic cancer disease [27]. However, the 
RANK/RANKL axis affects cellular functions far beyond bone metabolism, among which the 
involvement in malignant disease, especially in solid tumors, is increasingly appreciated [19,28]. 
This is exemplified by the elegant work of Tan and coworkers, who showed that tumor-infiltrating 
regulatory T cells facilitate breast cancer metastasis via RANK/RANKL interaction [29]. Metastasis 
formation is a complex process which is largely influenced by various factors including the tumor 
microenvironment and cancer-cell-intrinsic processes, but also by platelets and immune cells 
including NK cells [6]. We report here that the RANK/RANKL system may influence NK 
cell-mediated immunosurveillance of solid tumor cells following the interaction of the latter with 
platelets. 
i . Functional role of plat let-derived RANKL in NK cell reactivity against solid tumors.
(A) RANKL surface xpression on the indicated tumor cells was inv stigated by fl w cytometry.
(B–G) The indicated tumor cells were incubated in the presence or absence of platelets from HD.
Coating was performed as escribed in the Materials and Methods section. (B) RANKL and CD41a
surface expression on the indicated platelet-coated tumor cells was investigated by flow cytometry.
(C) pNK cells were cultured in the presence or absence of the indicated tumor cells and platelets from
HD. IFNγ levels in the culture supernatants were determined by ELISA after 24 h. (D) p K cells ere
co-cultured ith CF-7 cells in the presence or absence of platelets fro D. The effect of K cell
reactivity on tu or cell proliferation/survival was assessed by xCELLigence RTCA for 72 h. Results
are shown as electrical impedance signal (given as normalized cell index). Cell index was normalized
after addition of NK cells to the tumor cells. (E) pNK cells were cultured in the presence or absence
of the indicated tumor cells and platelets from HD. Where denoted, denosumab (10 µg/mL) or the
respective isotype control was applied. IFNγ levels in the culture supernatants were determined by
ELISA after 24 h. (F) pNK cells were treated as indicated in (E) and analyzed as in (D). (G) NK92 cells
were treated and analyzed as described in (E). (C–G) Representative data of one experiment from a
total of at least three with similar results are shown. Statistically significantly different results (p < 0.05)
are indicated by *.
3. Discussion
RANKL and its cognate receptors RANK and osteoprotegerin play a key role in regulating bone
metabolism [26]. Besides maintaining bone turnover in normal bone physiology, RANK also mediates
osteolytic lesions in the context of metastatic cancer disease [27]. However, the RANK/RANKL axis
affects cellular functions far beyond bone metabolism, among which the involvement in malignant
disease, especially in solid tumors, is increasingly appreciated [19,28]. This is exemplified by the
elegant work of Tan and coworkers, who showed that tumor-infiltrating regulatory T cells facilitate
breast cancer metastasis via RANK/RANKL interaction [29]. Metastasis formation is a complex
process which is largely influenced by various factors including the tumor microenvironment and
cancer-cell-intrinsic processes, but also by platelets and immune cells including NK cells [6]. We report
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here that the RANK/RANKL system may influence NK cell-mediated immunosurveillance of solid
tumor cells following the interaction of the latter with platelets.
In a panel of TNFR family members, RANK was found to be specifically upregulated on NK cells
of patients with solid tumors as compared to healthy individuals. This is in line with previous data
that various TNF and TNFR family members are upregulated on NK cells in the context of malignant
disease, where they modulate antitumor reactivity upon interaction with their cognate counterparts
on tumor cells [30,31]. RANKL was recently reported to be expressed on platelets, prompting us to
comparatively assess the expression of this and other TNF family members on platelets of cancer
patients and healthy donors [17]. The expression profile of the investigated ligands varied a lot among
different patients, alike that of their respective receptors on the lymphocytes. This extends available
data on the expression of TNF family molecules on platelets [32–34]. No difference regarding the
activation level of platelets ex vivo from patients with different stages of disease was observed which
may be due to the relatively small number of cases in our cohort studied. Interestingly, platelets
from cancer patients displayed lower levels of the TNF family ligands despite the fact that activation,
which should occur upon interaction with malignant cells, generally results in enhanced surface
expression. Potential explanations for this seemingly counterintuitive finding could be provided by a
reprogrammed megakaryopoiesis that occurs in cancer patients [35]. In addition, TNF family members
can be shed from the ligand expressing cells following interaction with their cognate receptor [36],
and this may be facilitated by the reportedly higher levels of proteolytic matrix metalloproteases
detectable on platelets from patients with metastasized disease compared to healthy controls [13].
While further work is required to unravel the mechanisms, based on our observation that cancer
patients display a highly patient-specific phenotypic imprint, specific expression patterns of the
investigated molecules and particularly RANK/RANKL on lymphocytes and platelets, it is tempting
to speculate that this “immunologic phenotype” may influence disease pathophysiology and could
serve as further prognostic factor when established and correlated with disease progression upon
analysis of a larger patient cohort.
Our findings that RANK triggering impaired NK cell reactivity against solid tumor cells extend
our previous data on the role of the RANK/RANKL axis in hematopoietic malignancies [19]. Notably,
the solid cancer cells do not have to express RANKL themselves to evade NK cell immunity [37],
but rather acquire RANKL-mediated immune privilege upon coating by platelets, which facilitates
activation of the latter and thus leads to increased expression of platelet-derived RANKL levels.
Platelet-derived RANKL then impairs NK antitumor reactivity with a more pronounced effect on IFNγ
production as compared to cytotoxicity, which is again in line with observations on the differential
effect of RANK/RANKL interaction on NK reactivity in hematological malignancies. Notably, release
of IFNγ by NK cells in response to tumor cells that is reinforced by denosumab treatment not only
may mediate direct antitumor effects but also stimulates subsequent adaptive immune responses.
In this context it is of particular interest that effects of denosumab occur very early, as confirmed by
our ELISA of supernatants obtained after 24 hours of co-culture. The fact that denosumab, which
is approved for treatment of osteoporosis and skeletal-related events in cancer patients, restored
platelet-mediated suppression of NK reactivity not only confirmed the specific involvement of RANKL;
it also provides a potential explanation for recent clinical findings obtained upon application of
denosumab for prevention of skeletal-related events in breast cancer patients, which suggest that
denosumab treatment may influence disease-free survival [28]. While these findings and our data
certainly require additional investigation, drug repurposing of denosumab for prevention of metastatic
events is appealing since it can be readily translated to the clinic due to its availability. Considering
that presently multiple approaches evaluate the clinical efficacy of ex vivo expanded/activated NK
cells upon adoptive transfer [21,22] the possibility to reinforce NK reactivity by RANKL blockade is
particularly attractive, since we found that ex vivo expanded pNK cells express high RANK levels
that, upon interaction with RANKL, inhibit their reactivity.
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Altogether, we provide evidence for a new modality of platelet-mediated immune escape of
solid tumors. Our findings open up new roads to use denosumab, alone or in combination with NK
cell transfer, for cancer therapy, even if substantial further preclinical work is required before cancer
patients ultimately may benefit from our observations.
4. Materials and Methods
4.1. Reagents
Recombinant human RANKL (rhRANKL) was from PeproTech (Rocky Hill, NJ, USA).
Paraformaldehyde was from Affymetrix (Santa Clara, CA, USA). Thrombin was obtained from
Sigma-Aldrich (St. Louis, MO, USA). Denosumab was from Amgen (Thousand Oaks, CA, USA).
The respective isotype control was purchased from Sigma-Aldrich. Anti-CD40L antibody was
from BioLegend (San Diego, CA, USA), the anti-CD40-PE conjugate was from BD Pharmingen
(San Diego, CA, USA). Anti-GITR, anti-GITRL, anti-HVEM, and anti-LIGHT antibodies were from
R&D Systems (Minneapolis, MN, USA). Anti-OX40 and anti-OX40L antibodies were from Ancell
Corporation (Bayport, MN, USA). For staining of RANK, a recombinant Fc-RANKL was produced as
described [38], the corresponding isotype control was purchased from R&D Systems and both were
biotinylated with the One-step biotinylation kit according to the manufacturer’s instructions (Miltenyi
Biotec, Bergisch Gladbach, Germany). Anti-RANKL antibody was from Acris Antibodies (Herford,
Germany). The respective isotype controls were from BioLegend or BD Pharmingen. CD19-FITC,
CD41a-PeCy5, and CD62P-FITC were from BD Pharmingen, CD3-APC/Fire and CD56-PECy7 were
obtained from BioLegend. The goat anti-mouse PE conjugate was from Dako (Glostrup, Denmark),
the streptavidin-PE conjugate was from BD Pharmingen. Dead cells were excluded using Fixable
Aqua (Invitrogen, Carlsbad, CA, USA) after extracellular staining according to the manufacturer’s
instructions. KPL TMB Microwell Peroxidase Substrate System (2-C) was obtained from SeraCare
Life Science (Milford, MA, USA), Streptavidin-Poly-HRP20 Conjugate was from Fitzgerald Industries
International (North Acton, MA, USA). Bicoll Separating Solution was purchased from Biochrom AG
(Berlin, Germany).
4.2. Cell Lines
The tumor cell lines MCF-7 and HCT 116 were from German Collection of Microorganisms and
Cell Cultures (Braunschweig, Germany). The NK cell line NK92MI2 (in the following named NK92)
was kindly provided by K. Dennehy (Institute for Medical Virology, University Hospital Tuebingen,
Tuebingen, Germany) [39,40].
4.3. Patients
Blood samples of patients with colorectal carcinoma or breast cancer were obtained after written
informed consent in accordance with the Helsinki protocol, and the study was performed according to
the guidelines of the local Ethics Committee. Patients comprised 9 cases of breast cancer and 11 cases
of colorectal carcinoma. For further patient characteristics see Table 1. The study was approved by IRB
(ethics committee of the Faculty of Medicine of the Eberhard Karls Universität Tuebingen) and of the
University Hospital Tuebingen and was conducted in accordance with the Declaration of Helsinki;
reference number 456/2017BO2, approval date was 21 September 2017.
4.4. Preparation of PBMC, NK Cells, and Platelets
PBMC were isolated by Ficoll/Bicoll density gradient centrifugation of blood from healthy
volunteers and where indicated, cultured for three days in RPMI-1640 medium containing GlutaMAX
and 25 mM HEPES supplemented with 10% FCS and 1% penicillin/streptomycin. pNK cells
were generated by culturing non-plastic adherent PBMC from HD with K562-41BBL-IL15 feeder
cells obtained from St. Jude’s Children’s Research Hospital (Memphis, TN, USA) as described
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previously [41]. pNK cells with a RANK surface expression above 70% were used for functional
experiments which were performed when purity of NK cells (CD56+CD3−) was >90%. Platelets
were obtained as described previously [12]. For platelet activation, 0.2 IU/mL thrombin was added
to washed platelets and the suspension was shaken gently for 1 min. Subsequent fixation with 2%
paraformaldehyde for 10 min was followed by two washing steps with PBS containing 1% FCS.
Platelets were obtained from HD not taking any medication for at least 10 d before blood collection.
4.5. Treatment of Tumor Cells with Platelets
Tumor cells lines were coated with platelets as described previously with slight
modifications [3,16]. In brief, tumor cells were incubated with washed platelets at a total of 50,000
platelets/µL for 30 min at 37 ◦C. For investigation of NK cell cytotoxicity, tumor cells were washed
afterwards to remove surplus platelets and soluble factors.
4.6. Flow Cytometry
Flow cytometry was performed using fluorescence-conjugates or unlabeled/biotinylated mAb at
saturating concentrations followed by a goat anti-mouse PE conjugate or a streptavidin-PE conjugate
(both 1:100) as secondary antibodies. Analysis was performed using a FACS Canto or a FACS Fortessa
(both BD Biosciences, Heidelberg, Germany). Percent positive cells were calculated as follows: “percent
surface expression obtained with specific antibody” − “percent surface expression obtained with
isotype control”. B cells were characterized by CD19+, T cells by CD3+, and NK cells by CD56+CD3−.
Platelets were selected by CD41a+ and CD62P− (resting) or CD62P+ (activated).
4.7. Cytotoxicity Assay
Tumor cells were co-cultured with pNK cells in the presence or absence of the indicated
compounds in 96-well plates (E-Plate 96, ACEA Biosciences, San Diego, CA, USA) at 10,000 tumor
cells/well. Effector to target cell ratio was 2.5:1. Real-time cell analysis was performed at 30 min
intervals during a 72 h observation period using the xCELLigence RTCA system (Roche Applied
Science, Penzberg, Germany). If not indicated otherwise, values are depicting means of technical
triplicates with standard deviation.
4.8. Determination of IFNγ
IFNγ levels were analyzed by ELISA using the ELISA mAb set from Thermo Scientific (Rockford,
IL, USA) according to manufacturer’s instructions. If not indicated otherwise, values are depicting
means of technical triplicates with standard deviation.
4.9. Statistics
The 95% confidence level was used and p-values were calculated with a Student’s t test in the
case of normally distributed data. Significance of not normally distributed data was calculated with
a Wilcoxon signed-rank test. Multiple comparisons were performed using an ordinary one-way
ANOVA for normally distributed data or a Kruskal-Wallis test for not normally distributed data with
subsequent Dunnett’s multiple comparisons test.
5. Conclusions
Here we report on a novel mechanism of immune evasion mediated by platelets. Our data also
provide a functional explanation for recent clinical observations that neutralization of RANKL by
denosumab, beyond protection from bone loss, prolongs disease-free survival in patients with solid
tumors as observed in breast cancer.
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6. Patents
Helmut R. Salih and Stefanie Maurer are inventors on a patent from the University of Tuebingen
that involves the role of platelet-derived RANKL in tumor immunity and its therapeutic modulation.
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Author Contributions: Conceptualization, H.R.S. and S.M.; methodology, K.L.C., S.M., and P.S.; software, K.L.C.
and S.M.; validation, S.M. and K.L.C.; formal analysis, K.L.C., S.M., and C.H.; investigation, K.L.C. and S.M.;
resources, H.R.S., C.H., and P.S.; data curation, K.L.C. and S.M.; writing—original draft preparation, K.L.C.
and S.M.; writing—review and editing, H.R.S.; visualization, K.L.C. and S.M.; supervision, H.R.S.; project
administration, K.L.C. and S.M.; funding acquisition, H.R.S.
Funding: H.R.S. was funded by Deutsche Forschungsgemeinschaft, SA1360/7-3, Wilhelm Sander-Stiftung,
2007.115.3, and Deutsche Krebshilfe, 111828, 111134. S.M. is supported by the Institutional Strategy of the
University of Tuebingen (Deutsche Forschungsgemeinschaft, ZUK 63). P.S. is supported by the Swiss National
Science Foundation, 31003A-176256. We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publishing Fund of University of Tübingen.
Acknowledgments: The authors thank Celine Reiss for excellent technical assistance, Ulrich Lauer for providing
the xCELLigence system, and Kevin Dennehy for providing the NK cell line NK92MI2. Flow cytometry sample
acquisition was performed on shared instruments of the Flow Cytometry Core Facility Tuebingen.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Gasic, G.J.; Gasic, T.B.; Stewart, C.C. Antimetastatic effects associated with platelet reduction. Proc. Natl.
Acad. Sci. USA 1968, 61, 46–52. [CrossRef] [PubMed]
2. Gay, L.J.; Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11,
123–134. [CrossRef] [PubMed]
3. Labelle, M.; Begum, S.; Hynes, R.O. Direct signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20, 576–590. [CrossRef]
[PubMed]
4. Placke, T.; Kopp, H.G.; Salih, H.R. Modulation of Natural Killer Cell Anti-Tumor Reactivity by Platelets.
J. Innate Immun. 2011, 4, 374–382. [CrossRef] [PubMed]
5. Nieswandt, B.; Hafner, M.; Echtenacher, B.; Mannel, D.N. Lysis of tumor cells by natural killer cells in mice is
impeded by platelets. Cancer Res. 1999, 59, 1295–1300. [PubMed]
6. Lopez-Soto, A.; Gonzalez, S.; Smyth, M.J.; Galluzzi, L. Control of Metastasis by NK Cells. Cancer Cell 2017,
32, 135–154. [CrossRef] [PubMed]
7. Lanier, L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23, 225–274. [CrossRef] [PubMed]
8. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian
biology. Cell 2001, 104, 487–501. [CrossRef]
9. Wild, J.; Schmiedel, B.J.; Maurer, A.; Raab, S.; Prokop, L.; Stevanovic, S.; Dorfel, D.; Schneider, P.; Salih, H.R.
Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic
lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia 2015, 29, 1676–1683. [CrossRef]
[PubMed]
10. Nuebling, T.; Schumacher, C.E.; Hofmann, M.; Hagelstein, I.; Schmiedel, B.J.; Maurer, S.; Federmann, B.;
Rothfelder, K.; Roerden, M.; Dorfel, D.; et al. The Immune Checkpoint Modulator OX40 and Its Ligand
OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. Cancer Immunol. Res. 2018, 6, 209–221.
[CrossRef] [PubMed]
11. Liu, B.; Li, Z.; Mahesh, S.P.; Pantanelli, S.; Hwang, F.S.; Siu, W.O.; Nussenblatt, R.B. Glucocorticoid-induced
tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells
by blocking proliferative signals and increasing NK cell apoptosis. J. Biol. Chem. 2008, 283, 8202–8210.
[CrossRef] [PubMed]
Cancers 2019, 11, 277 14 of 15
12. Kopp, H.G.; Placke, T.; Salih, H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D
thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009, 69, 7775–7783. [CrossRef]
[PubMed]
13. Maurer, S.; Kropp, K.N.; Klein, G.; Steinle, A.; Haen, S.P.; Walz, J.S.; Hinterleitner, C.; Marklin, M.; Kopp, H.G.;
Salih, H.R. Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor
cells. Oncoimmunology 2018, 7, e1364827. [CrossRef] [PubMed]
14. Gasser, S.; Raulet, D.H. Activation and self-tolerance of natural killer cells. Immunol. Rev. 2006, 214, 130–142.
[CrossRef] [PubMed]
15. Placke, T.; Oergel, M.; Schaller, M.; Jung, G.; Rammensee, H.G.; Kopp, H.G.; Salih, H.R. Platelet-derived
MHC Class I confers a pseudo- normal phenotype to cancer cells that subverts the anti-tumor reactivity of
natural killer immune cells. Cancer Res. 2011, 72, 440–448. [CrossRef] [PubMed]
16. Placke, T.; Salih, H.R.; Kopp, H.G. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor
activity. J. Immunol. 2012, 189, 154–160. [CrossRef] [PubMed]
17. Nakanishi, T.; Inaba, M.; Inagaki-Katashiba, N.; Tanaka, A.; Vien, P.T.; Kibata, K.; Ito, T.; Nomura, S.
Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal
lymphopoietin. Platelets 2015, 26, 425–431. [CrossRef] [PubMed]
18. Schmiedel, B.J.; Grosse-Hovest, L.; Salih, H.R. A “vicious cycle” of NK-cell immune evasion in acute myeloid
leukemia mediated by RANKL? Oncoimmunology 2013, 2. [CrossRef] [PubMed]
19. Schmiedel, B.J.; Nuebling, T.; Steinbacher, J.; Malinovska, A.; Wende, C.M.; Azuma, M.; Schneider, P.;
Grosse-Hovest, L.; Salih, H.R. Receptor Activator for NF-kappaB Ligand in Acute Myeloid Leukemia:
Expression, Function, and Modulation of NK Cell Immunosurveillance. J. Immunol. 2013, 190, 821–831.
[CrossRef] [PubMed]
20. Gruss, H.J.; Dower, S.K. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant
lymphomas. Blood 1995, 85, 3378–3404. [PubMed]
21. Handgretinger, R.; Lang, P.; Andre, M.C. Exploitation of natural killer cells for the treatment of acute
leukemia. Blood 2016, 127, 3341–3349. [CrossRef] [PubMed]
22. Zingoni, A.; Sornasse, T.; Cocks, B.G.; Tanaka, Y.; Santoni, A.; Lanier, L.L. Cross-talk between activated
human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 2004, 173, 3716–3724.
[CrossRef] [PubMed]
23. Suck, G.; Odendahl, M.; Nowakowska, P.; Seidl, C.; Wels, W.S.; Klingemann, H.G.; Tonn, T. NK-92: An
‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol.
Immunother. 2016, 65, 485–492. [CrossRef] [PubMed]
24. Cummings, S.R.; San Martin, J.; McClung, M.R.; Siris, E.S.; Eastell, R.; Reid, I.R.; Delmas, P.; Zoog, H.B.;
Austin, M.; Wang, A.; et al. Denosumab for prevention of fractures in postmenopausal women with
osteoporosis. N. Engl. J. Med. 2009, 361, 756–765. [CrossRef] [PubMed]
25. Smith, M.R.; Egerdie, B.; Hernandez, T.N.; Feldman, R.; Tammela, T.L.; Saad, F.; Heracek, J.; Szwedowski, M.;
Ke, C.; Kupic, A.; et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
N. Engl. J. Med. 2009, 361, 745–755. [CrossRef] [PubMed]
26. Hofbauer, L.C.; Neubauer, A.; Heufelder, A.E. Receptor activator of nuclear factor-kappaB ligand and
osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases.
Cancer 2001, 92, 460–470. [CrossRef]
27. Roodman, G.D.; Dougall, W.C. RANK ligand as a therapeutic target for bone metastases and multiple
myeloma. Cancer Treat. Rev. 2008, 34, 92–101. [CrossRef] [PubMed]
28. Gnant, M.; Pfeiler, G.; Dubsky, P.C.; Hubalek, M.; Greil, R.; Jakesz, R.; Wette, V.; Balic, M.; Haslbauer, F.;
Melbinger-Zeinitzer, E.; et al. The impact of adjuvant denosumab on disease-free survival: Results from
3,425 postmenopausal patients of the ABCSG-18 trial. Cancer Res. 2016. [CrossRef]
29. Tan, W.; Zhang, W.; Strasner, A.; Grivennikov, S.; Cheng, J.Q.; Hoffman, R.M.; Karin, M. Tumour-infiltrating
regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011,
470, 548–553. [CrossRef] [PubMed]
30. Baessler, T.; Krusch, M.; Schmiedel, B.J.; Kloss, M.; Baltz, K.M.; Wacker, A.; Schmetzer, H.M.; Salih, H.R.
Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance
of acute myeloid leukemia in humans. Cancer Res. 2009, 69, 1037–1045. [CrossRef] [PubMed]
Cancers 2019, 11, 277 15 of 15
31. Baessler, T.; Charton, J.E.; Schmiedel, B.J.; Grunebach, F.; Krusch, M.; Wacker, A.; Rammensee, H.G.;
Salih, H.R. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell
reactivity against human acute myeloid leukemia cells. Blood 2010, 115, 3058–3069. [CrossRef] [PubMed]
32. Henn, V.; Slupsky, J.R.; Grafe, M.; Anagnostopoulos, I.; Forster, R.; Muller-Berghaus, G.; Kroczek, R.A. CD40
ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391, 591–594.
[CrossRef] [PubMed]
33. Ahmad, R.; Menezes, J.; Knafo, L.; Ahmad, A. Activated human platelets express Fas-L and induce apoptosis
in Fas-positive tumor cells. J. Leukoc. Biol. 2001, 69, 123–128. [CrossRef] [PubMed]
34. Crist, S.A.; Elzey, B.D.; Ludwig, A.T.; Griffith, T.S.; Staack, J.B.; Lentz, S.R.; Ratliff, T.L. Expression of
TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp. Hematol. 2004, 32,
1073–1081. [CrossRef] [PubMed]
35. Plantureux, L.; Mege, D.; Crescence, L.; Dignat-George, F.; Dubois, C.; Panicot-Dubois, L. Impacts of Cancer
on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. Cancers
2018, 10, 441. [CrossRef] [PubMed]
36. Yacoub, D.; Benslimane, N.; Al-Zoobi, L.; Hassan, G.; Nadiri, A.; Mourad, W. CD154 is released from T-cells
by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40
protein-dependent manner. J. Biol. Chem. 2013, 288, 36083–36093. [CrossRef] [PubMed]
37. Yamada, T.; Tsuda, M.; Takahashi, T.; Totsuka, Y.; Shindoh, M.; Ohba, Y. RANKL expression specifically
observed in vivo promotes epithelial mesenchymal transition and tumor progression. Am. J. Pathol. 2011,
178, 2845–2856. [CrossRef] [PubMed]
38. Schneider, P.; Willen, L.; Smulski, C.R. Tools and techniques to study ligand-receptor interactions and receptor
activation by TNF superfamily members. Methods Enzymol. 2014, 545, 103–125. [CrossRef] [PubMed]
39. Dennehy, K.M.; Klimosch, S.N.; Steinle, A. Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK
cytotoxicity. J. Immunol. 2011, 186, 657–661. [CrossRef] [PubMed]
40. Tam, Y.K.; Maki, G.; Miyagawa, B.; Hennemann, B.; Tonn, T.; Klingemann, H.G. Characterization
of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular
immunotherapy. Hum. Gene Ther. 1999, 10, 1359–1373. [CrossRef] [PubMed]
41. Koerner, S.P.; Andre, M.C.; Leibold, J.S.; Kousis, P.C.; Kubler, A.; Pal, M.; Haen, S.P.; Buhring, H.J.;
Grosse-Hovest, L.; Jung, G.; et al. An Fc-optimized CD133 antibody for induction of NK cell reactivity
against myeloid leukemia. Leukemia 2016. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
